We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Artificial Intelligence Method That Improves Lab Test Management Discussed at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Illustration
Illustration

Results from an evaluation of an artificial intelligence (AI) method that improves test utilization and reimbursement were presented by Patients Choice Laboratories (Indianapolis, IN, USA) at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Of the five billion lab orders submitted each year, at least 20% are considered inappropriate. These inappropriate tests can lead to slower or incorrect diagnoses for patients. Such tests may also not be covered by Medicare if they weren’t meant to be used for particular medical conditions or if they were ordered with the wrong ICD-10 diagnostic codes, which in turn raises health costs.

Patients Choice Laboratories set out to determine if an automated test management system known as the Laboratory Decision System (LDS) could help improve test ordering. The LDS scores potential tests based on medical necessity and testing indication, helping providers minimize test misutilization and select the best tests for a given medical condition.

Using LDS, the researchers re-evaluated a total of 374,423 test orders from a reference laboratory, 48,049 of which had not met the criteria for coverage under Medicare. For 96.4% of the first 10,000 test claims, the LDS ranking system recommended alternative tests that better matched the medical necessity or had a more appropriate ICD-10 code. Of these recommendations, 80.5% would also meet Medicare policies. All of this indicates that the LDS could help correct mistaken or inappropriate lab orders.

“Our study implies that use of the automated test ordering system LDS would be extremely helpful for providers, laboratories, and payers,” said Dr. Rojeet Shrestha, PhD, of Patients Choice Laboratories. “Use of this algorithm-based testing selection and ordering database, which rates and scores potential tests for any given disease based on clinical relevance, medical necessity, and testing indication, would eventually help providers to select and order the right test and reduce over- and under-utilization of tests.”

Related Links:
Patients Choice Laboratories

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.